GB2568698A - Formulation - Google Patents
Formulation Download PDFInfo
- Publication number
- GB2568698A GB2568698A GB1719464.8A GB201719464A GB2568698A GB 2568698 A GB2568698 A GB 2568698A GB 201719464 A GB201719464 A GB 201719464A GB 2568698 A GB2568698 A GB 2568698A
- Authority
- GB
- United Kingdom
- Prior art keywords
- excipient
- apocynin
- paeonol
- isomer
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 238000009472 formulation Methods 0.000 title claims abstract description 47
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 claims abstract description 140
- DFYRUELUNQRZTB-UHFFFAOYSA-N apocynin Chemical compound COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 claims abstract description 140
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 claims abstract description 72
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 claims abstract description 69
- 229930188866 apocynin Natural products 0.000 claims abstract description 67
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 42
- 150000001875 compounds Chemical class 0.000 claims abstract description 33
- 239000012669 liquid formulation Substances 0.000 claims abstract description 21
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract description 15
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims abstract description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000000374 eutectic mixture Substances 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 7
- 150000002148 esters Chemical class 0.000 claims abstract description 6
- 150000005846 sugar alcohols Polymers 0.000 claims abstract description 6
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 5
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 4
- 125000003827 glycol group Chemical group 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 101001006370 Actinobacillus suis Hemolysin Proteins 0.000 description 18
- 241000196324 Embryophyta Species 0.000 description 13
- 239000007788 liquid Substances 0.000 description 12
- 239000002775 capsule Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 9
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 229930182470 glycoside Natural products 0.000 description 5
- 150000002338 glycosides Chemical class 0.000 description 5
- XPHIPEXPAGCEBM-UHFFFAOYSA-N 2-methoxy-4-hydroxyacetophenone Natural products COC1=CC(O)=CC=C1C(C)=O XPHIPEXPAGCEBM-UHFFFAOYSA-N 0.000 description 3
- QSPOERJDZBVCJH-UHFFFAOYSA-N Kutkin Natural products COc1cc(ccc1OC2OC(CO)C(O)C(O)C2O)C(O)(OC)C(=O)OC=Cc3ccccc3 QSPOERJDZBVCJH-UHFFFAOYSA-N 0.000 description 3
- XSIQHIDJSCQWBB-QHJBZRDQSA-N [(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] 3-methoxy-4-[(E)-3-phenylprop-2-enoyl]oxybenzoate dihydrate Chemical compound O.O.COc1cc(ccc1OC(=O)\C=C\c1ccccc1)C(=O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XSIQHIDJSCQWBB-QHJBZRDQSA-N 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- VZEOJJIAYZCDPI-UHFFFAOYSA-N 1-(2-hydroxy-3-methoxyphenyl)ethanone Chemical compound COC1=CC=CC(C(C)=O)=C1O VZEOJJIAYZCDPI-UHFFFAOYSA-N 0.000 description 2
- 241000722949 Apocynum Species 0.000 description 2
- 240000005001 Paeonia suffruticosa Species 0.000 description 2
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 2
- 244000290333 Vanilla fragrans Species 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- NLSMPWTZYGSAEU-CYUNEVMDSA-N (2s,3r,4s,5s,6r)-2-[7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromenylium-5-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;chloride Chemical compound [Cl-].C1=C(O)C(OC)=CC(C=2C(=CC=3C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC(O)=CC=3[O+]=2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 NLSMPWTZYGSAEU-CYUNEVMDSA-N 0.000 description 1
- QUOZWMJFTQUXON-UXXRCYHCSA-N 1-[3-methoxy-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]ethanone Chemical compound COC1=CC(C(C)=O)=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QUOZWMJFTQUXON-UXXRCYHCSA-N 0.000 description 1
- QUOZWMJFTQUXON-UHFFFAOYSA-N Androsin Natural products COC1=CC(C(C)=O)=CC=C1OC1C(O)C(O)C(O)C(CO)O1 QUOZWMJFTQUXON-UHFFFAOYSA-N 0.000 description 1
- IRLNKOAURQPXIQ-WWWUCTDISA-N Apiopaeonoside Natural products O=C(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO[C@H]3[C@H](O)[C@@](O)(CO)CO3)O2)cc(OC)cc1 IRLNKOAURQPXIQ-WWWUCTDISA-N 0.000 description 1
- 241000879217 Apocynum androsaemifolium Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 241000124449 Paeonia obovata Species 0.000 description 1
- 241000124464 Paeonia veitchii Species 0.000 description 1
- IDZZECHGWAZTIB-NYBIBFQCSA-N Paeonolide Chemical compound COC1=CC=C(C(C)=O)C(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@@H](O)CO3)O)O2)O)=C1 IDZZECHGWAZTIB-NYBIBFQCSA-N 0.000 description 1
- IDZZECHGWAZTIB-WPQJODJHSA-N Paeonolide Natural products O=C(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]3[C@@H](O)[C@H](O)[C@@H](O)CO3)O2)cc(OC)cc1 IDZZECHGWAZTIB-WPQJODJHSA-N 0.000 description 1
- AVIUTYMRHHBXPB-UXXRCYHCSA-N Paeonoside Natural products COC1=CC=C(C(C)=O)C(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 AVIUTYMRHHBXPB-UXXRCYHCSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 240000001745 Rheum palmatum Species 0.000 description 1
- 235000008090 Rheum palmatum Nutrition 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- XZGPUOQGERGURE-LUVHZPKESA-N [(2r,3s,4s,5r,6s)-6-[[(1as,1bs,2s,5ar,6s,6as)-6-hydroxy-1a-(hydroxymethyl)-2,5a,6,6a-tetrahydro-1bh-oxireno[5,6]cyclopenta[1,3-c]pyran-2-yl]oxy]-3,4,5-trihydroxyoxan-2-yl]methyl (e)-3-phenylprop-2-enoate Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@H]1OC=C[C@H]2[C@H](O)[C@@H]3O[C@@]3([C@@H]12)CO)OC(=O)\C=C\C1=CC=CC=C1 XZGPUOQGERGURE-LUVHZPKESA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- IDZZECHGWAZTIB-UHFFFAOYSA-N affinoside Natural products COC1=CC=C(C(C)=O)C(OC2C(C(O)C(O)C(COC3C(C(O)C(O)CO3)O)O2)O)=C1 IDZZECHGWAZTIB-UHFFFAOYSA-N 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- SCIGYBYAZUFDLA-YRWPAIAPSA-N globularin Natural products OC[C@H]1O[C@@H](O[C@@H]2OC=C[C@H]3[C@H](O)[C@@H]4O[C@]4(COC(=O)C=Cc5ccccc5)[C@@H]23)[C@H](O)[C@@H](O)[C@@H]1O SCIGYBYAZUFDLA-YRWPAIAPSA-N 0.000 description 1
- AVIUTYMRHHBXPB-UHFFFAOYSA-N glucopaeonol Natural products COC1=CC=C(C(C)=O)C(OC2C(C(O)C(O)C(CO)O2)O)=C1 AVIUTYMRHHBXPB-UHFFFAOYSA-N 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229930182491 iridoid glucoside Natural products 0.000 description 1
- 229930182489 iridoid glycoside Natural products 0.000 description 1
- 150000008145 iridoid glycosides Chemical class 0.000 description 1
- XFFQVRFGLSBFON-DEFKTLOSSA-N kaempferol 3,7-di-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C(C=3C=CC(O)=CC=3)OC2=C1 XFFQVRFGLSBFON-DEFKTLOSSA-N 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229930194807 paeonin Natural products 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- KEUKDVIGAVVGLF-RUYHYXBRSA-N picroside I Natural products OC[C@]12O[C@H]1[C@@H]3O[C@@H](O[C@@H]4O[C@H](COC(=O)C=Cc5ccccc5)[C@@H](O)[C@H](O)[C@H]4O)C=C[C@@H]3[C@H]2O KEUKDVIGAVVGLF-RUYHYXBRSA-N 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Priority Applications (30)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1719464.8A GB2568698A (en) | 2017-11-23 | 2017-11-23 | Formulation |
| CN202310468972.2A CN116999417A (zh) | 2017-11-23 | 2018-11-22 | 包含丹皮酚和罗布麻宁的液体制剂 |
| PL18810956T PL3713546T3 (pl) | 2017-11-23 | 2018-11-22 | Ciekła formulacja zawierająca paeonol i apocyninę |
| KR1020207018001A KR102758107B1 (ko) | 2017-11-23 | 2018-11-22 | 페오놀 및 아포시닌을 포함하는 액체 제형 |
| HUE18810956A HUE057595T2 (hu) | 2017-11-23 | 2018-11-22 | Paeonolt és apocinint tartalmazó folyékony formuláció |
| CN201880075175.5A CN111372572B (zh) | 2017-11-23 | 2018-11-22 | 包含丹皮酚和罗布麻宁的液体制剂 |
| ES18810956T ES2906761T3 (es) | 2017-11-23 | 2018-11-22 | Formulación líquida que comprende paeonol y apocinina |
| MX2020005313A MX393836B (es) | 2017-11-23 | 2018-11-22 | Formulacion liquida que comprende paeonol y apocinina |
| HRP20220303TT HRP20220303T1 (hr) | 2017-11-23 | 2018-11-22 | Tekuća formulacija koja sadrži peonol i apocinin |
| NZ764238A NZ764238B2 (en) | 2018-11-22 | Liquid formulation comprising paeonol and apocynin | |
| SI201830590T SI3713546T1 (sl) | 2017-11-23 | 2018-11-22 | Tekoča formulacija, ki obsega paeonol in apocinin |
| LTEPPCT/EP2018/082178T LT3713546T (lt) | 2017-11-23 | 2018-11-22 | Skysta kompozicija, apimani paeonolį ir apokininą |
| EP21209333.0A EP4019005A1 (en) | 2017-11-23 | 2018-11-22 | Liquid formulation comprising paeonol and apocynin |
| AU2018371165A AU2018371165B2 (en) | 2017-11-23 | 2018-11-22 | Liquid formulation comprising paeonol and apocynin |
| JP2020545869A JP7314157B2 (ja) | 2017-11-23 | 2018-11-22 | ペオノール及びアポシニンを含む液体製剤 |
| KR1020257001687A KR20250013306A (ko) | 2017-11-23 | 2018-11-22 | 페오놀 및 아포시닌을 포함하는 액체 제형 |
| RS20220135A RS62923B1 (sr) | 2017-11-23 | 2018-11-22 | Tečna formulacija koja sadrži paeonol i apocinin |
| US16/765,627 US11701325B2 (en) | 2017-11-23 | 2018-11-22 | Liquid formulation comprising paeonol and apocynin |
| CA3082945A CA3082945A1 (en) | 2017-11-23 | 2018-11-22 | Liquid formulation comprising paeonol and apocynin |
| SM20220101T SMT202200101T1 (it) | 2017-11-23 | 2018-11-22 | Formulazione liquida comprendente paeonolo e apocinina |
| EP18810956.5A EP3713546B1 (en) | 2017-11-23 | 2018-11-22 | Liquid formulation comprising paeonol and apocynin |
| DK18810956.5T DK3713546T3 (da) | 2017-11-23 | 2018-11-22 | Flydende formulering omfattende paeonol og apocynin |
| PT188109565T PT3713546T (pt) | 2017-11-23 | 2018-11-22 | Formulação líquida compreendendo paeonol e apocinina |
| PCT/EP2018/082178 WO2019101842A1 (en) | 2017-11-23 | 2018-11-22 | Liquid formulation comprising paeonol and apocynin |
| MX2022008551A MX2022008551A (es) | 2017-11-23 | 2020-07-13 | Formulacion liquida que comprende paeonol y apocinina. |
| CY20221100119T CY1124986T1 (el) | 2017-11-23 | 2022-02-10 | Υγρο σκευασμα που περιλαμβανει παεονολη και αποκυνινη |
| JP2023079234A JP2023104963A (ja) | 2017-11-23 | 2023-05-12 | ペオノール及びアポシニンを含む液体製剤 |
| US18/327,202 US20230330017A1 (en) | 2017-11-23 | 2023-06-01 | Liquid formulation comprising paeonol and apocynin |
| AU2024203514A AU2024203514B2 (en) | 2017-11-23 | 2024-05-27 | Liquid formulation comprising paeonol and apocynin |
| JP2025022755A JP2025065531A (ja) | 2017-11-23 | 2025-02-14 | ペオノール及びアポシニンを含む液体製剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1719464.8A GB2568698A (en) | 2017-11-23 | 2017-11-23 | Formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB201719464D0 GB201719464D0 (en) | 2018-01-10 |
| GB2568698A true GB2568698A (en) | 2019-05-29 |
Family
ID=60950758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1719464.8A Withdrawn GB2568698A (en) | 2017-11-23 | 2017-11-23 | Formulation |
Country Status (21)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2568698A (en) * | 2017-11-23 | 2019-05-29 | Akl Res & Development Ltd | Formulation |
| GB202218160D0 (en) * | 2022-12-02 | 2023-01-18 | Akl Res & Development Ltd | Formulation |
| CN119033608B (zh) * | 2024-11-01 | 2025-03-25 | 深圳杉海创新技术有限公司 | 一种具有抑菌作用的低共熔溶剂、微脂囊及其制备方法与应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2424833A (en) * | 2005-04-08 | 2006-10-11 | Nicholas John Larkins | Anti-inflammatory formulation |
| GB2463080A (en) * | 2008-09-02 | 2010-03-03 | Nicholas John Larkins | Pharmaceutical preparation |
| WO2013037843A1 (en) * | 2011-09-12 | 2013-03-21 | Akl Inflammatory Limited | Formulation for the treatment of benign prostate hyperplasia |
| GB2547241A (en) * | 2016-02-11 | 2017-08-16 | Akl Res & Dev Ltd | Anti-inflammatory formulation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR920700613A (ko) * | 1989-05-16 | 1992-08-10 | 지구르트 퓌터 | 약제제 |
| CN100544708C (zh) * | 2004-08-18 | 2009-09-30 | 上海佰加壹医药有限公司 | 一种丹皮酚软胶囊及其制备方法 |
| GB201416909D0 (en) * | 2014-09-25 | 2014-11-12 | Prosonix Ltd | Method of forming concentrated solution |
| GB2568698A (en) * | 2017-11-23 | 2019-05-29 | Akl Res & Development Ltd | Formulation |
-
2017
- 2017-11-23 GB GB1719464.8A patent/GB2568698A/en not_active Withdrawn
-
2018
- 2018-11-22 EP EP21209333.0A patent/EP4019005A1/en active Pending
- 2018-11-22 HR HRP20220303TT patent/HRP20220303T1/hr unknown
- 2018-11-22 HU HUE18810956A patent/HUE057595T2/hu unknown
- 2018-11-22 ES ES18810956T patent/ES2906761T3/es active Active
- 2018-11-22 JP JP2020545869A patent/JP7314157B2/ja active Active
- 2018-11-22 KR KR1020257001687A patent/KR20250013306A/ko active Pending
- 2018-11-22 MX MX2020005313A patent/MX393836B/es unknown
- 2018-11-22 LT LTEPPCT/EP2018/082178T patent/LT3713546T/lt unknown
- 2018-11-22 CN CN201880075175.5A patent/CN111372572B/zh active Active
- 2018-11-22 PL PL18810956T patent/PL3713546T3/pl unknown
- 2018-11-22 WO PCT/EP2018/082178 patent/WO2019101842A1/en not_active Ceased
- 2018-11-22 RS RS20220135A patent/RS62923B1/sr unknown
- 2018-11-22 EP EP18810956.5A patent/EP3713546B1/en active Active
- 2018-11-22 US US16/765,627 patent/US11701325B2/en active Active
- 2018-11-22 CA CA3082945A patent/CA3082945A1/en active Pending
- 2018-11-22 PT PT188109565T patent/PT3713546T/pt unknown
- 2018-11-22 SI SI201830590T patent/SI3713546T1/sl unknown
- 2018-11-22 KR KR1020207018001A patent/KR102758107B1/ko active Active
- 2018-11-22 SM SM20220101T patent/SMT202200101T1/it unknown
- 2018-11-22 CN CN202310468972.2A patent/CN116999417A/zh active Pending
- 2018-11-22 DK DK18810956.5T patent/DK3713546T3/da active
- 2018-11-22 AU AU2018371165A patent/AU2018371165B2/en active Active
-
2020
- 2020-07-13 MX MX2022008551A patent/MX2022008551A/es unknown
-
2022
- 2022-02-10 CY CY20221100119T patent/CY1124986T1/el unknown
-
2023
- 2023-05-12 JP JP2023079234A patent/JP2023104963A/ja active Pending
- 2023-06-01 US US18/327,202 patent/US20230330017A1/en active Pending
-
2024
- 2024-05-27 AU AU2024203514A patent/AU2024203514B2/en active Active
-
2025
- 2025-02-14 JP JP2025022755A patent/JP2025065531A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2424833A (en) * | 2005-04-08 | 2006-10-11 | Nicholas John Larkins | Anti-inflammatory formulation |
| GB2463080A (en) * | 2008-09-02 | 2010-03-03 | Nicholas John Larkins | Pharmaceutical preparation |
| WO2013037843A1 (en) * | 2011-09-12 | 2013-03-21 | Akl Inflammatory Limited | Formulation for the treatment of benign prostate hyperplasia |
| GB2547241A (en) * | 2016-02-11 | 2017-08-16 | Akl Res & Dev Ltd | Anti-inflammatory formulation |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2024203514B2 (en) | Liquid formulation comprising paeonol and apocynin | |
| WO2014002599A1 (ja) | 生薬等含有医薬組成物 | |
| US9913869B2 (en) | Formulations comprising herbal extracts | |
| CN103989668A (zh) | 连翘苷元在制备预防或治疗肝损伤或肝衰竭药物中的应用 | |
| US11090346B2 (en) | Cannabinoid composition and method of sublingual, buccal and oral mucosa delivery | |
| CN101057674B (zh) | 一种用于防治糖尿病的组合物 | |
| CN106380459A (zh) | 一种降脂的黄酮类化合物 | |
| CN102475698A (zh) | 丹酚酸l在制备治疗肿瘤药物中的应用 | |
| US20260130964A1 (en) | Pharmaceutical composition comprising high pay load ginger extract granules and process for preparation thereof | |
| CN118576681A (zh) | 一种保肝护肝的组合物及其制备方法 | |
| CN115105514B (zh) | 一种保护胃黏膜、治疗胃溃疡的药物组合物及其制备方法和应用 | |
| CN113214207A (zh) | 橙皮素与甜菜碱共晶物a及制备方法和其组合物与用途 | |
| CN106176711B (zh) | 包含类黄酮化合物组合物的药物及其应用 | |
| CN109453149B (zh) | 吉马酮在制备防治银屑病的药物中的应用 | |
| KR100485936B1 (ko) | 진세노사이드 Rh2 및 Rg3 항암 조성물 | |
| TW200946140A (en) | Stable-type Cucurbitacin medicinal liquid compositions | |
| KR20250071993A (ko) | 용출률과 안정성이 향상된 밀크시슬 함유 경구 투여용 제제 및 그 제조방법 | |
| CN115645422A (zh) | 用于预防和治疗代谢综合征的组合物及其用途 | |
| WO2013042131A1 (en) | A process for preparation of synergistic herbal preparation of extracts picrorhiza kurroa and glycyrrhiza glabra having medicinal value | |
| CN104147024A (zh) | 一种白藜芦醇衍生物的新用途 | |
| WO2016093680A1 (ru) | Препарат на основе субстанции растительного происхождения, обладающий гепатопротекторным действием | |
| HK40028810A (en) | Composition comprising isoferulic acid for use in the treatment of autoimmune hepatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |